Next Investors logo grey

Creso agreement with Health House sees first shipment of medical cannabis into Australia


Published 02-MAY-2017 13:30 P.M.


4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Shares in Creso Pharma (ASX:CPH) could receive significant support after the company announced that it had formalized an agreement with its partner in Australia, Health House International Pty Ltd (Health House), following Health House’s successful import of the first medicinal cannabis products into Australia.

It should be noted that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

Creso and Health House have entered the agreement for an initial two-year term (with an option of extension), subject to Health House International purchasing and importing the agreed minimum quantities of product.

This agreement and the successful first import of medicinal cannabis products by Health House to Australian patients is a groundbreaking achievement for Creso Pharma and Health House and an important milestone at a time when the medical cannabis industry in Australia is growing rapidly.

Creso ahead of the curve and well-funded to capture market share in Australia

The agreement and import follows Health House being granted a Federal import license in February this year as part of the Australian Federal Government’s move to authorize the importation of medical cannabis from international sources to boost domestic supply until local production increases.

Highlighting the significance of this development, CPH’s co-founder and chairman Boaz Wachtel said, “The Australian medical cannabis market is an important one for Creso and this agreement positions us strategically to help meet the immediate but unmet need and timely access to medicinal cannabis here in Australia.”

While there are a number of players operating in the cannabis development space, CPH is one of the more advanced in terms of bringing product to market, and its execution in terms of developing a vertically integrated business has been faultless.

The company brings pharmaceutical expertise and methodological rigour to the world of medicinal cannabis and strives for the highest quality in its products. It is the leader in cannabidiol (CBD) innovation and develops cannabis and hemp-derived therapeutic-grade CBD nutraceuticals and medical cannabis products with wide patient reach for human and animal health.

CPH cashed up for growth through product development and entry into new markets

Not only is CPH well-positioned strategically in terms of entering numerous markets including Australia, but following a recent substantially oversubscribed placement of $8 million and a subsequently well supported Share Purchase Plan of $1 million, the company has a cash position of circa $11 million.

Key areas outlined by management regarding the use of these funds include fast tracking the commercialisation of CPH’s cannabinoid derived animal and human health nutraceuticals and other medical products.

The company will be investing in expanding the group’s development pipeline with additional products that utilise innovative delivery technologies in order to optimise bioactivity and absorption of cannabinoids.

The funds will also be used to assist the company in penetrating new geographic regions, which will provide additional sources of revenue.

First import includes three oils produced by CPH’s Canadian partner CanniMed

The successful first import involved a range of three cannabis oils (high CBD 1:20, high THC 18:0 and mixture THC/CBD oils 10:10) for human health from Creso’s Canadian partner, medical cannabis group, CanniMed®. The oils will be used for the treatment of a variety of indications as approved by the prescribing physicians under Australian Federal and State laws and regulations.

Wachtel underlined the fact that medical cannabis has been shown in a number of countries around the world to be an effective health treatment for a variety of conditions and Cannimed’s first rate supplies into Australia will help patients enormously, especially those in acute pain or with chronic conditions.”

Health House will now distribute the CanniMed® products across Australia in authorized pharmacies in compliance with Federal and State legislation.

Health House International Director Paul Mavor said, “We are excited to be working with Creso Pharma and playing a key part in the Australian Government’s efforts to improve access to medicinal cannabis in the local market.”

In highlighting the quality of the products being sourced through the relationship with CPH and CanniMed, Mavcor said, “Being able to supply Australians with some of the world’s best medical cannabis oils is a tremendous achievement and will make it far easier for patients to access, under doctor’s prescription, medical cannabis from overseas sources.”

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.